Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other ...

Pneumocystis pneumonia is a condition caused by a microorganism called Pneumocystis jiroveci. This has been reclassified in recent years as a fungus due to its characteristic nucleotide sequences and ...

Tulane University researchers have developed a CRISPR-based test that diagnoses Pneumocystis jirovecii pneumonia (PJP)—a life ...

What are the options for Pneumocystis jirovecii pneumonia prophylaxis? The preferred agent is TMP–SMX. 2 Dosing regimens include 1 double-strength tablet 3 times per week or 1 single-strength tablet ...

This type of pneumonia is rare but can be dangerous for those with weakened immune systems. Treatment and diagnosis processes have come a long way in the last few decades. Pneumocystis pneumonia (PCP) ...

The group led by Dr. Enrique J. Calderón - "Clinical Epidemiology and Vascular Risk" at the Institute of Biomedicine of Seville - IBiS/University Hospitals Virgen ...

A review of phase 3 clinical trials of CDK4/6 inhibitor combination therapy in premenopausal women. A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for ...

Pneumocystis jirovecii pneumonia (PJP) is the most common fungal pneumonia in children. But current diagnostic methods can take days an require an invasive bronchoscopy procedure. Now, a new ...